Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanaria PfSPZ-CVac
- Development stage
- Unknown
- Lead developer
- Sanaria
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
**Sanaria PfSPZ-CVac** is a second-generation, chemo-attenuated whole sporozoite malaria vaccine developed by Sanaria Inc. against *Plasmodium falciparum* (Pf), the deadliest human malaria parasite. It consists of live, non-replicating Pf sporozoites (PfSPZ) co-administered with antimalarial drugs such as chloroquine (CQ) or pyrimethamine (PYR) to attenuate parasites by killing them during brief liver-stage multiplication, inducing potent T cell and antibody responses for sterile protection. More immunogenic than radiation-attenuated PfSPZ Vaccine at lower doses, it has demonstrated up to 100% efficacy against homologous and heterologous CHMI strains in Phase 1/2 trials and high protection against natural transmission in field studies in Africa and Indonesia, targeting children, adults, and travelers in endemic areas.[1][2][3][7]
- Other names
- PfSPZ-CVac (CQ)PfSPZ-CVac (PYR)
Beyond the preview
Go deeper on Sanaria PfSPZ-CVac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sanaria PfSPZ-CVac.